JP2024105479A5 - - Google Patents

Download PDF

Info

Publication number
JP2024105479A5
JP2024105479A5 JP2024076658A JP2024076658A JP2024105479A5 JP 2024105479 A5 JP2024105479 A5 JP 2024105479A5 JP 2024076658 A JP2024076658 A JP 2024076658A JP 2024076658 A JP2024076658 A JP 2024076658A JP 2024105479 A5 JP2024105479 A5 JP 2024105479A5
Authority
JP
Japan
Prior art keywords
cell population
hematopoietic
hematopoietic cell
cells
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024076658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024105479A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/048317 external-priority patent/WO2019046285A1/en
Application filed filed Critical
Publication of JP2024105479A publication Critical patent/JP2024105479A/ja
Publication of JP2024105479A5 publication Critical patent/JP2024105479A5/ja
Pending legal-status Critical Current

Links

JP2024076658A 2017-08-28 2024-05-09 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 Pending JP2024105479A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762551075P 2017-08-28 2017-08-28
US62/551,075 2017-08-28
PCT/US2018/048317 WO2019046285A1 (en) 2017-08-28 2018-08-28 CD33 EXON 2 DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS
JP2020511435A JP2020531535A (ja) 2017-08-28 2018-08-28 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020511435A Division JP2020531535A (ja) 2017-08-28 2018-08-28 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Publications (2)

Publication Number Publication Date
JP2024105479A JP2024105479A (ja) 2024-08-06
JP2024105479A5 true JP2024105479A5 (cg-RX-API-DMAC7.html) 2024-11-01

Family

ID=65525985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511435A Pending JP2020531535A (ja) 2017-08-28 2018-08-28 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞
JP2024076658A Pending JP2024105479A (ja) 2017-08-28 2024-05-09 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020511435A Pending JP2020531535A (ja) 2017-08-28 2018-08-28 Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞

Country Status (4)

Country Link
US (2) US11718659B2 (cg-RX-API-DMAC7.html)
EP (1) EP3676372A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020531535A (cg-RX-API-DMAC7.html)
WO (1) WO2019046285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL258491B2 (en) 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
JP7784707B2 (ja) * 2019-01-16 2025-12-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 系統特異的抗原の阻害のための組成物および方法
AU2020280103A1 (en) 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
AU2020338011A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
WO2021041977A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
US12551560B2 (en) 2019-09-09 2026-02-17 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
EP4048790A4 (en) * 2019-10-22 2024-03-27 Fred Hutchinson Cancer Center BASE EDITOR-MEDIATED CD33 REDUCTION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
CN116157135A (zh) * 2020-06-03 2023-05-23 纽约市哥伦比亚大学理事会 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法
EP4204564A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cd123 modification
EP4204565A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
CA3199623A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
CN116600821A (zh) * 2020-10-27 2023-08-15 Vor生物制药股份有限公司 用于治疗造血系统恶性肿瘤的组合物和方法
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
AU2021413252A1 (en) 2020-12-31 2023-06-08 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
PE20252304A1 (es) * 2021-04-28 2025-09-22 Eisai Randd Man Co Ltd Oligonucleotidos antisentido y su uso para el tratamiento de trastornos neurodegenerativos
EP4430186A1 (en) 2021-11-09 2024-09-18 Vor Biopharma Inc. Compositions and methods for erm2 modification
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
IL320040A (en) * 2022-10-05 2025-06-01 Musc Found For Res Dev Superantigen conjugate vaccine for cancer treatment
WO2024168312A1 (en) * 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
US10201606B2 (en) * 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3439700A4 (en) * 2016-04-06 2020-01-01 University of Florida Research Foundation, Inc. BIOMARKER FOR ANTILEUCEMIC THERAPY
KR102709603B1 (ko) * 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33

Similar Documents

Publication Publication Date Title
Diorio et al. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Voehringer et al. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)
Yang et al. Challenges and opportunities of allogeneic donor-derived CAR T cells
JP2020531535A5 (cg-RX-API-DMAC7.html)
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
AU2025205147A1 (en) Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
Clark et al. Cultured human follicular dendritic cells. Growth characteristics and interactions with B lymphocytes
Veuillen et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy
Oh et al. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
US12398402B2 (en) Reducing CD33 expression to selectively protect therapeutic cells
CN113227141A (zh) 抗cd33免疫细胞癌症疗法
EP3757133A1 (en) Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
US20250041339A1 (en) Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy
Kujawski et al. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
JP2023528415A5 (cg-RX-API-DMAC7.html)
JP2024515920A (ja) 固形腫瘍標的化骨格を有する細胞及びその使用
Yu et al. In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method
Dourthe et al. CAR T-cells for T-cell acute lymphoblastic leukemia
US12295973B2 (en) Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells
US20250170182A1 (en) Epitope engineering of cell-surface receptors
US20220195441A1 (en) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
WO2023250433A2 (en) Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them
US20240139321A1 (en) Universal car-t cell targeting gd2, preparation method therefor, and application thereof
EP4295860A1 (en) Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them
WO2022040277A1 (en) Constitutively active tcf1 to promote memory-associated traits in car t cells